The present invention discloses a cannabinoid-based composition useful for treating or preventing dental pulp associated diseases. The composition comprises an effective amount of Cannabis extract or a derivative thereof or at least one synthetic cannabinoid for the treatment of dental pulp inflammation, pulp infection and/or dental bone defects. The present invention further discloses methods for treating or preventing dental pulp associated diseases.

The present invention discloses a cannabinoid-based composition useful for treating or preventing dental pulp associated diseases. The composition comprises an effective amount of Cannabis extract or a derivative thereof or at least one synthetic cannabinoid for the treatment of dental pulp inflammation, pulp infection and/or dental bone defects. The present invention further discloses methods for treating or preventing dental pulp associated diseases.

A kit includes a multi-phase oral composition for whitening teeth and an electromagnetic radiation source. The multi-phase oral composition for whitening teeth includes from about 0.002% to about 30%, by weight of the multi-phase oral composition, of a discontinuous aqueous phase having a bleaching agent, where a concentration of the bleaching agent is up to 10%, by weight of the multi-phase oral composition, and at least about 50%, by weight of the multi-phase oral composition, of a continuous hydrophobic phase of petrolatum. The electromagnetic radiation source is capable of directing electromagnetic radiation with one or more wavelength in the range from about 200 nm to about 1700 nm toward at least one tooth. The electromagnetic radiation source emits electromagnetic radiation in a range from about 100 mW/cm.sup.2 to about 250 mW/cm.sup.2.

The present invention belongs to the field of medicine, and relates to a compound

##STR00001##

of Formula I and a pharmaceutically acceptable salt thereof for using as a MAGL inhibitor, as well as a preparation method and use thereof, and an intermediate for preparing the same.

The disclosure relates to oral care compositions comprising guanidine in free or orally acceptable salt form and a stannous ion source (e.g., stannous fluoride) as well as to methods of using and of making these compositions.

The present invention relates to a salivary gland therapeutic agent using the effects of a cell-derived vesicle of enhancing the proliferation capacity of salivary gland cells, promoting an amylase activity, and enhancing transepithelial resistance. A pharmaceutical composition comprising the cell-derived vesicle according to the present invention has the effects of enhancing the proliferation capacity of salivary gland cells damaged by radiation, promoting amylase activity, increasing transepithelial resistance, enhancing the expression of Aquaporin 5, and increasing the amount of saliva secretion. Therefore, the pharmaceutical composition comprising the cell-derived vesicle of the present invention can be used for preventing and treating salivary gland diseases, and thus can be widely used in the pharmaceutical industry and health functional food field.

The present invention relates to a salivary gland therapeutic agent using the effects of a cell-derived vesicle of enhancing the proliferation capacity of salivary gland cells, promoting an amylase activity, and enhancing transepithelial resistance. A pharmaceutical composition comprising the cell-derived vesicle according to the present invention has the effects of enhancing the proliferation capacity of salivary gland cells damaged by radiation, promoting amylase activity, increasing transepithelial resistance, enhancing the expression of Aquaporin 5, and increasing the amount of saliva secretion. Therefore, the pharmaceutical composition comprising the cell-derived vesicle of the present invention can be used for preventing and treating salivary gland diseases, and thus can be widely used in the pharmaceutical industry and health functional food field.

The present invention provides a method of promoting local bone growth by administering a therapeutic amount of a Sost antagonist to a mammalian patient in need thereof. Preferably, the Sost antagonist is an antibody or FAB fragment selectively recognizing any one of SEQ ID NOS: 1-23. The Sost antagonist may be coadministered together or sequentially with a matrix conducive to anchoring new bone growth. Orthopedic and Periodontal devices comprising an implantable portion adapted to be permanently implanted within a mammalian body and bearing an external coating of a Sost antagonist are also disclosed, as it a method of increasing bone density by administering to a mammalian patient a therapeutic amount of a Sost antagonist together with an antiresorptive drug.

The present invention provides novel probiotic formulation for Liver health and enhancing immunity comprising a combination of specific probiotic bacterial strains belonging to the genera Lactobacillus and Bifidobacterium. The invention also provides a probiotic formulation for oral health. The said probiotic formulations are unique in being a low water activity blend and consist of oro-dispersible properties.

A self-film-forming composition in powder form, a reconstituted formula and a kit for oral use are provided, which allow an adequate colonization of the probiotic in the oral cavities together with a sufficient residence time to allow beneficial effects against the pathogens related with oral conditions. Thus, the items provided are useful for the prevention and/or treatment of a condition related to alterations of the oral microbiota, and specifically for peri-implantitis. The self-film-forming composition in powder form comprises at least a gelifier agent and/or at least a bioadhesive agent, and at least one lactic acid bacteria strain.